Cogent Biosciences announced that its PEAK Phase III clinical trial for gastrointestinal stromal tumors (GIST) has achieved positive results, and the study has been selected for the oral presentation session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$6 billion acquisition! Medical giant Bausch Health plans to take a controlling stake in Surgery Partners (SGRY.US)
Boston Consulting Group plans to acquire a controlling stake in Surgery Partners for approximately $6 billions, at $20 per share; Bain Capital will retain a 40% stake, and the deal could be announced as early as Monday.
Solana added 22 million euros worth of stablecoins in one week.
SK Hynix plans to distribute special dividends totaling about $12 billion.
$40 billion spent on GPUs! Elon Musk says SpaceX (SPCX.US) off-balance-sheet financing is settled, slams "new cloud" sector will be a bloodbath
Elon Musk stated that SpaceX has completed a $40 billions debt transaction to purchase chips in support of its artificial intelligence (AI) initiatives.
Crypto prices
More
